The ‘highly skilled’ team at VISCHER acts for a diverse client base of medtech, digital health, and pharma companies in matters concerning the market launch of products, off-label use, and cross-border IVF related issues. Stefan Kohler and Matthias Staehelin jointly lead the team from Zurich and Basel respectively. Staehelin is an expert in transactional matters within the life sciences sector, frequently advising on seed and series financings, M&A, and royalty purchase agreements. Kohler advises both Swiss and overseas corporates on technology transfers and R&D agreements, all whilst acting as an associate judge in the Swiss Federal Patent Court. Christian Wyss is known for handling a broad range of issues, including partnering deals and fundraisings, regularly assisting investors, start-ups, and license terms.
Testimonials
Collated independently by Legal 500 research team.
‘This is one of the best firms I have worked together with. The reason for this is specifically Christian Wyss. Their work is highly diligent and they find innovative but market-proven ways on how to reach a desired outcome.’
- ‘Highly skilled, fast-to-respond, agile, flexible, great collaboration and communication.’
Key clients
- Redbiotec
- Mosanna Therapeutics
- Forty51 Ventures
- Norgine Ventures
- Versantis
- Oculis
- Anokion
- Resistell
- AMR Action Fund
- GlycoEra AG
- Medartis
- ATANIS Biotech
- Sustainable Health AG
- Thermo Fisher Scientific
- Bausch Health
- ten23 Health AG
- Bachem Holding AG
- CombiGene AB
- Anjarium Biosciences AG
- Novaremed
- Spexis
- Combioxin SA
- evitria Group
- ImmunOs Therapeutics AG
- Anaveon AG
- Cimeio Therapeutics
- MiniNaviDent AG
- T3 Pharmaceuticals
- ClearView Healthcare Partners
- RELIEF THERAPEUTICS HOLDING SA
Work highlights
- Advised AMR Action Fund, a public-private partnership investing in new antimicrobial therapeutics, in leading the CHF 32.6m Series C financing of BioVersys AG.
- Advised Oculis Holding SA on listing its shares at Nasdaq via a SPAC transaction with European Biotech Acquisition Corp.
- Represented ten23 Health against a leading pharmaceutical company before the Swiss Federal Patent Court. ten23 Health's manufacturing activities for a biosimilar in ophthalmology were challenged.
Lawyers
Practice head
The lawyer(s) leading their teams.
Stefan Kohler, Matthias Staehelin